305 related articles for article (PubMed ID: 20672371)
1. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
[TBL] [Abstract][Full Text] [Related]
2. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
Ansari M; Lauzon-Joset JF; Vachon MF; Duval M; Théoret Y; Champagne MA; Krajinovic M
Bone Marrow Transplant; 2010 Feb; 45(2):261-7. PubMed ID: 19584821
[TBL] [Abstract][Full Text] [Related]
3. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
[TBL] [Abstract][Full Text] [Related]
4. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
[TBL] [Abstract][Full Text] [Related]
5. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients.
Ansari M; Rezgui MA; Théoret Y; Uppugunduri CR; Mezziani S; Vachon MF; Desjean C; Rousseau J; Labuda M; Przybyla C; Duval M; Champagne M; Peters C; Bittencourt H; Krajinovic M;
Bone Marrow Transplant; 2013 Jul; 48(7):939-46. PubMed ID: 23292236
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
7. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
Kim SD; Lee JH; Hur EH; Lee JH; Kim DY; Lim SN; Choi Y; Lim HS; Bae KS; Noh GJ; Yun SC; Han SB; Lee KH
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1222-30. PubMed ID: 21215809
[TBL] [Abstract][Full Text] [Related]
8. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
9. Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation.
Al-Riyami I; Al-Khabori M; Al Balushi K; Al-Zadjali S; Al-Rawahi M; Dennison D; Al-Hunaini M; Al-Rawas A; Al-Moundhri M
Ther Drug Monit; 2022 Aug; 44(4):527-534. PubMed ID: 34990437
[TBL] [Abstract][Full Text] [Related]
10. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
11. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M; Théoret Y; Rezgui MA; Peters C; Mezziani S; Desjean C; Vachon MF; Champagne MA; Duval M; Krajinovic M; Bittencourt H;
Ther Drug Monit; 2014 Feb; 36(1):93-9. PubMed ID: 24061446
[TBL] [Abstract][Full Text] [Related]
12. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
13. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
Kusama M; Kubota T; Matsukura Y; Matsuno K; Ogawa S; Kanda Y; Iga T
Clin Chim Acta; 2006 Jun; 368(1-2):93-8. PubMed ID: 16448639
[TBL] [Abstract][Full Text] [Related]
14. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
Ansari M; Huezo-Diaz P; Rezgui MA; Marktel S; Duval M; Bittencourt H; Cappelli B; Krajinovic M
Bone Marrow Transplant; 2016 Mar; 51(3):377-83. PubMed ID: 26691424
[TBL] [Abstract][Full Text] [Related]
15. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
Nguyen L; Leger F; Lennon S; Puozzo C
Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
[TBL] [Abstract][Full Text] [Related]
16. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
17. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT.
ten Brink MH; Wessels JA; den Hartigh J; van der Straaten T; von dem Borne PA; Guchelaar HJ; Zwaveling J
Bone Marrow Transplant; 2012 Feb; 47(2):190-5. PubMed ID: 21441958
[TBL] [Abstract][Full Text] [Related]
18. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.
Kim MG; Kwak A; Choi B; Ji E; Oh JM; Kim K
Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):691-703. PubMed ID: 30511436
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
20. Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.
Bremer S; Fløisand Y; Brinch L; Gedde-Dahl T; Bergan S
Ther Drug Monit; 2015 Aug; 37(4):493-500. PubMed ID: 25565670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
